Publicacions en què col·labora amb Eva Bandres Elizalde (66)

2013

  1. MicroRNAs in colorectal cancer

    MicroRNAs in Cancer (CRC Press), pp. 177-219

  2. Valoración de marcadores pronósticos de respuesta a bevacizumab en pacientes con cáncer colorrectal avanzado y su utilidad para la individualización del tratamiento

    Anales del sistema sanitario de Navarra, Vol. 36, Núm. 1, pp. 174-177

2012

  1. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

    European Journal of Cancer, Vol. 48, Núm. 12, pp. 1774-1780

  2. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array

    World Journal of Gastroenterology, Vol. 18, Núm. 7, pp. 637-645

  3. Identification of predictive circulating biomarkers of bevacizumab- containing regimen efficacy in pre-treated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 107, Núm. 2, pp. 287-290

  4. MiRNAs and lincRNAs: Could they be considered as biomarkers in colorectal cancer?

    International Journal of Molecular Sciences, Vol. 13, Núm. 1, pp. 840-865

2011

  1. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

  2. Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma

    BJU International, Vol. 107, Núm. 11, pp. 1833-1838

  3. DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer

    Oncogene, Vol. 30, Núm. 6, pp. 668-678

  4. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas

    PLoS ONE, Vol. 6, Núm. 10

  5. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells

    Stem Cells, Vol. 29, Núm. 11, pp. 1661-1671

  6. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer

    Journal of Surgical Oncology, Vol. 103, Núm. 5, pp. 411-415

  7. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan

    Pharmacogenomics Journal, Vol. 11, Núm. 6, pp. 429-436

2010

  1. A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on B-lymphocyte lineage cells

    Pharmaceutical Research, Vol. 27, Núm. 3, pp. 431-441

  2. Development of a DNA microelectrochemical biosensor for CEACAM5 detection

    IEEE Sensors Journal, Vol. 10, Núm. 8, pp. 1368-1374

  3. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535

  4. MicroRNAs as a new potential therapeutic opportunity in gastrointestinal cancer

    Oncology, Vol. 77, Núm. SUPPL. 1, pp. 75-89

  5. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation

    Molecular Cancer Therapeutics, Vol. 9, Núm. 8, pp. 2265-2275

2009

  1. Epigenetic regulation of microRNA expression in colorectal cancer

    International Journal of Cancer, Vol. 125, Núm. 11, pp. 2737-2743

  2. Gene expression profile related to oxaliplatin (OXA) intrinsic resistance in a panel of 14 human colorectal cancer (CRC) cell lines

    EJC SUPPLEMENTS